Observational study in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03673306 (A Multicenter Retrospective Study on the Prognostic Impact of Pregnancy in Women With History of BRCA Mutated Breast Cancer), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eva BlondeauxU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.ORCID 0000-0001-9566-4579
Virginia DelucchiU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Elene MariamidzeDepartment of Oncology and Haematology, Todua Clinic, Tbilisi, Georgia.ORCID 0000-0001-8838-9193
Rinat Bernstein-MolhoSusanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Centre affiliated to Tel Aviv University, Tel Hashomer, Israel.ORCID 0000-0002-4068-9514
Alberta FerrariHereditary Breast and Ovarian Cancer (HBOC) Unit and General Surgery 3-Senology, Surgical Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0003-2525-3787
Sabine LinnDepartment of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.ORCID 0000-0001-5541-0347
Hee Jeong KimDivision of Breast Surgery, Department of Surgery, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0002-1343-8138
Shani Paluch-ShimonBreast Oncology Unit, Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.ORCID 0000-0002-6677-2199
Laura CortesiDepartment of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.ORCID 0000-0001-8950-8561
Antonio Di MeglioCancer Survivorship Program-Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.ORCID 0000-0002-0233-3189
Judith BalmanaHereditary Cancer Genetics Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-0762-6415
Rinat YerushalmiDavidoff Centre, Rabin Medical Centre, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-6221-2859
Kenny A Rodriguez-WallbergDepartment of Oncology/Pathology, Karolinska Institute and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0003-4378-6181
Tiphaine RenaudCancer Genetics Unit, Bergonie Institute, Bordeaux, France.
Wanda CuiDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-5077-6814
Halle C F MooreDepartment of Haematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States.ORCID 0000-0002-7472-9350
Stephanie M WongStroll Cancer Prevention Centre, Jewish General Hospital, and McGill University Medical School, Montreal, QC, Canada.ORCID 0000-0002-6850-2192
Katarzyna PogodaDepartment of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID 0000-0002-9902-711X
Maryam LustbergCenter for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center, New Haven, CT, United States.
Kelly-Anne PhillipsDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-0475-1771
Sileny HanDepartment of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-7476-3372
Fabio PuglisiDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID 0000-0003-0573-4938
Claudio VernieriMedical Oncology Department, Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0003-1577-8176
Jyoti BajpaiTata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
Christine Rousset-JablonskiDepartment of Surgery, Leon Berard Cancer Centre, Lyon, France.ORCID 0000-0001-7087-5687
Laura De MarchisDivision of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-2195-7955
Ugo De GiorgiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0001-7520-2908
Giampaolo BianchiniDepartment of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-6790-6267
Francois P DuhouxCliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.ORCID 0000-0002-5429-7888
Cynthia Villarreal-GarzaBreast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.ORCID 0000-0003-3587-339X
Valentina SiniMedical Oncology, Centro Oncologico Santo Spirito-Nuovo Regina Margherita, Rome, Italy.
Lucia Del MastroMedical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-9546-5841
Isabelle DemeestereDepartment of Obstetrics and Gynaecology, Fertility Clinic HUB Erasme (U.L.B), Brussels, Belgium.ORCID 0000-0002-3192-6565
Hatem A AzimCairo Cure Oncology Centre, Cairo, Egypt.
Fedro A PeccatoriGynaecology Oncology Program, European Institute of Oncology (IRCCS), Milan, Italy.ORCID 0000-0001-8227-8740
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.ORCID 0000-0002-4722-4824
Matteo LambertiniMedical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0003-1797-5296
Funding
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC (Diversity Supplement)R01CA159868 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOPPER, JOHN L, TERRY, MARY BETH · 2011 to 2015
$9.0M
2022 Gilead Research Scholars Program in Solid TumorsAIRC MFAG 2020Associazione Italiana per la Ricerca sul CancroBreast Cancer Research FoundationCancer Councils of New South WalesCancer Foundation of Western AustraliaEuropean Society for Medical OncologyItalian Association for Cancer ResearchKorea Health Industry Development InstituteKorea Health Technology R&DMinistry of Health and Welfare, Republic of Korea HC20C0135National Breast Cancer Foundation 1100868National Breast Cancer Foundation 809195National Health and Medical Research CouncilNational Health and Medical Research Council 145684National Health and Medical Research Council 288704National Health and Medical Research Council 454508NCI NIH HHS R01 CA159868NIH HHS 1RO1CA159868Queensland Cancer Fund
6 · The paper itself
Abstract
backgroundWe investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants.
methodsThis was an international, multicenter, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS), and overall survival (OS) were compared between patients who breastfed after delivery and those who did not.
resultsAmong 4732 patients included from 78 centers worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%). After a median follow-up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 36% in the no breastfeeding group (adjusted subdistribution hazard ratio [HR] = 1.08, 95% CI = 0.57 to 2.06). No difference in DFS (adjusted hazard ratio [aHR] = 0.83, 95% CI = 0.49 to 1.41) nor in OS (aHR = 1.32, 95% CI = 0.31 to 5.66) was observed.
conclusionsBreastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Breastfeeding after breast cancer in young BRCA carriers. · full record | OpenQuestion